Amneal Pharmaceuticals share price logo

Amneal Pharmaceuticals

NASDAQ: AMRX

Mid Cap

$19.18

-0.07

(-0.36%)

as on

Amneal Pharmaceuticals Stock Performance

as on October 17, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $18.94
    $19.33
    downward going graph

    1.25%

    Downside

    0.78%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $9.77
    $21.18
    downward going graph

    49.09%

    Downside

    10.40%

    Upside

    downward going graph

Amneal Pharmaceuticals share price movements today

Previous Close
$19.25
Open
$19.27
Volume
1.6M
Market Cap
$6.7B
Day's Low - High
$18.94 - $19.33
52 Week Low - High
$9.77 - $21.18

Amneal Pharmaceuticals Historical Returns

1 Month Return
+ 4.92 %
3 Month Return
+ 7.45 %
1 Year Return
+ 93.35 %
3 Year Return
+ 415.59 %
5 Year Return
+ 240.07 %

Amneal Pharmaceuticals Stock Fundamentals & Key Indicators

Check Amneal Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.7B

EPS (TTM)

0.5

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.57%

PE Ratio (TTM)

38.69

Industry PE ratio

21.91

PEG Ratio

0.01

EBITDA

652.2M

Revenue (TTM)

3.1B

Profit Margin

39.32%

Return On Equity TTM

-326.75%

Amneal Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Amneal Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$6.7B240.07%38.6939.32%0.00%
Buy$39.3BNA61.0147.54%1.13%
Buy$23.2B184.98%17.9186.14%0.00%
Buy$20.0B38.60%-50.6134.83%2.63%
Buy$42.3BNA20.6665.57%1.99%

Stock Returns calculator for Amneal Pharmaceuticals Stock including INR - Dollar returns

The Amneal Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Amneal Pharmaceuticals investment value today

Current value as on today

₹2,08,936

Returns

₹1,08,936

(+108.94%)

Returns from Amneal Pharmaceuticals Stock

₹93,347 (+93.35%)

Dollar Impact

₹15,589 (+15.59%)

Analyst Recommendation on Amneal Pharmaceuticals Stock

Based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 6 analysts, 100% of analysts recommend a 'BUY' rating for Amneal Pharmaceuticals. Average target price of $22.71

Amneal Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Amneal Pharmaceuticals.

What analysts predicted

15.54%UPSIDE

Target Price

$22.71

Current Price

$19.18

Analyzed by

6 Analysts

High

$27

Target

$22.71

Low

$17

Amneal Pharmaceuticals target price $22.71, a slight upside of 15.54% compared to current price of $19.18. According to 6 analysts rating.

Indian Investors' Interest in Amneal Pharmaceuticals Stock

Investment in Amneal Pharmaceuticals Shares on INDmoney has grown by 106.25% in the last 30 days, indicating increased investment activity.

Time period: to

Change:106.25% versus previous 30 day period

Search interest for Amneal Pharmaceuticals Stock has increased by 156% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:156% versus previous 30 day period

Amneal Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
659
701
702
730
695
724
784
814
722
796
Gross Profit
238
249
269
262
255
286
273
297
320
334
Operating Income
-10
95
88
75
100
111
0
114
142
145
EBITDA
45
141
139
112
154
176
111
160
186
193
Interest Expense
65
65
65
61
56
65
62
56
53
55
Depreciation
55
55
58
66
60
60
54
49
43
47
Income Before Tax
-75
20
15
-15
37
51
-5
55
80
70
Income Tax Expense
6
3
3
5
12
16
-23
5
2
1
Net Income
-91
5
0
-31
12
22
2
35
62
57
Net Profit Margin
36.11%
35.62%
38.37%
35.98%
36.80%
39.51%
34.92%
36.50%
44.31%
42.01%

Amneal Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,033
1,662
1,626
1,992
2,093
2,212
2,393
2,793
3,018
Gross Profit
526
716
352
628
768
791
863
1,020
1,136
Operating Income
245
-19
-248
91
152
-94
204
249
423
EBITDA
271
-19
155
345
401
440
500
439
603
Interest Expense
71
143
168
145
136
158
210
258
241
Depreciation
45
137
207
235
233
240
229
236
223
Income Before Tax
171
-202
-220
-35
31
-248
-40
-55
139
Income Tax Expense
1
-1
383
-104
11
6
8
18
11
Net Income
167
-169
-361
91
10
-129
-83
-116
72
Net Profit Margin
50.90%
43.08%
21.70%
31.54%
36.73%
35.78%
36.09%
36.52%
37.63%

Amneal Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-81
5
11
-20
24
35
18
49
78
69
Operating Cash Flow
-4
39
141
118
7
83
118
130
-28
-19
Investing Cash Flow
-19
-6
-20
-16
-17
-26
-22
-45
-21
-122
Financing Cash Flow
-23
-35
-92
-61
-39
-41
59
-10
-57
77
Change in Cash
-47
-1
28
40
-50
15
154
74
-109
-65

Amneal Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
169
-201
-603
91
10
-254
-48
-73
72
Operating Cash Flow
234
250
1
379
241
65
345
295
339
Investing Cash Flow
-98
-396
-19
-317
-194
-174
-69
-62
-112
Financing Cash Flow
-95
287
-45
131
-138
-106
-212
-211
-31
Change in Cash
40
140
-65
194
-90
-221
63
19
194

Global Institutional Holdings in Amneal Pharmaceuticals

Check out the Institutions with significant holdings in Amneal Pharmaceuticals.

Funds
Holdings
iShares
6.43%
Vanguard
5.26%
VANGUARD INDEX FUNDS
4.36%
Invesco
1.35%
SPDR
1.22%

Amneal Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 09 September

    Wed, 05:46 PM

    -

    Leerink initiates coverage of Amneal Pharmaceuticals with an Outperform rating, citing growth potential in affordable medicines and biosimilars.

Insights on Amneal Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 722.51M → 796.19M (in $), with an average increase of 9.3% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AMRX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, AMRX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, AMRX stock has moved up by 37.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 62.25M → 57.66M (in $), with an average decrease of 7.4% per quarter

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
OrganisationAmneal Pharmaceuticals
Headquarters400 Crossing Boulevard, Bridgewater, NJ, 08807, US
IndustryDrug Manufacturers - Specialty & Generic
CEOChirag K. Patel

Key Management of Amneal Pharmaceuticals

Name

Title

Mr. Gregory Sgammato

Senior Vice President of Corporate Development

Mr. Pranav Mehta

Senior VP of Strategic Sourcing & Supply Management

Mr. Chintu Patel R.Ph.

Co-Founder, Co-CEO & Director

Mr. Anastasios G. Konidaris

Executive VP & CFO

Mr. Jason B. Daly Esq.

Executive VP, Chief Legal Officer & Corporate Secretary

Ms. Nikita Shah

Executive VP & Chief Human Resources Officer

Mr. Anthony DiMeo

Head/VP of Investor Relations

Mr. Chirag K. Patel

Co-Founder, Co-CEO, President & Director

Mr. Andrew S. Boyer

Executive VP and Chief Commercial Officer of Generics & Biosciences

Brandon Skop

Senior Director of Corporate Communications

FAQs

What is Amneal Pharmaceuticals share price today?

Amneal Pharmaceuticals share price today is $19.18 as on at the close of the market. Amneal Pharmaceuticals share today touched a day high of $19.33 and a low of $18.94.

What is the 52 week high and 52 week low for Amneal Pharmaceuticals share?

Amneal Pharmaceuticals share touched a 52 week high of $21.18 on and a 52 week low of $9.77 on . Amneal Pharmaceuticals stock price today i.e. is closed at $19.18,which is 9.42% down from its 52 week high and 96.42% up from its 52 week low.

What is Amneal Pharmaceuticals's market capitalisation today?

Amneal Pharmaceuticals market capitalisation is $0.01T as on .

How to invest in Amneal Pharmaceuticals Stock (AMRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Amneal Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Amneal Pharmaceuticals Stock (AMRX) from India?

Indian investors can start investing in Amneal Pharmaceuticals (AMRX) shares with as little as ₹94.959999084473 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Amneal Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Amneal Pharmaceuticals share’s latest price of $19.18 as on October 17, 2026 at 8:45 am IST, you will get 0.5214 shares of Amneal Pharmaceuticals. Learn more about fractional shares .

What are the returns that Amneal Pharmaceuticals has given to Indian investors in the last 5 years?

Amneal Pharmaceuticals stock has given 240.07% share price returns and 26.39% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?